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Hypoxia-induced pulmonary hypertension (PH) is one of the most common and deadliest forms of PH. Fibroblast growth
factor receptors 1 and 2 (FGFR1/2) are elevated in patients with PH and in mice exposed to chronic hypoxia. Endothelial
FGFR1/2 signaling is important for the adaptive response to several injury types and we hypothesized that endothelial
FGFR1/2 signaling would protect against hypoxia-induced PH. Mice lacking endothelial FGFR1/2, mice with activated
endothelial FGFR signaling, and human pulmonary artery endothelial cells (HPAECs) were challenged with hypoxia. We
assessed the effect of FGFR activation and inhibition on right ventricular pressure, vascular remodeling, and endothelialmesenchymal transition (EndMT), a known pathologic change seen in patients with PH. Hypoxia-exposed mice lacking
endothelial FGFRs developed increased PH, while mice overexpressing a constitutively active FGFR in endothelial cells did
not develop PH. Mechanistically, lack of endothelial FGFRs or inhibition of FGFRs in HPAECs led to increased TGF-β signaling
and increased EndMT in response to hypoxia. These phenotypes were reversed in mice with activated endothelial FGFR
signaling, suggesting that FGFR signaling inhibits TGF-β pathway–mediated EndMT during chronic hypoxia. Consistent with
these observations, lung tissue from patients with PH showed activation of FGFR and TGF-β signaling. Collectively, these data
suggest that activation of endothelial FGFR signaling could be therapeutic for hypoxia-induced PH.

Introduction

Pulmonary hypertension (PH) is a severe form of pulmonary vascular disease that results in death in up to two-thirds of affected
patients within 5 years of diagnosis. There are 5 World Health
Organization subtypes of PH. Group 3 PH, the second deadliest
category of PH, is caused by hypoxemia resulting from developmental lung disorders such as bronchopulmonary dysplasia
(BPD), chronic obstructive lung disease (COPD), combined pulmonary fibrosis and emphysema (CPFE), interstitial lung disease,
alveolar hypoventilation disorders, or high altitude (1, 2).
PH increases the morbidity and mortality in patients with
COPD, BPD, and CPFE (3–5). Preterm birth affects more than
500,000 babies born in the United States each year and BPD is
the most common complication in preterm infants born before
29 weeks of gestation (3). Up to half of preterm infants with BPD
and PH die within 2 years of diagnosis (3). Five to ten percent of
patients with COPD are diagnosed with PH, and up to 64% of these
patients will die within 5 years (4, 6). First described by Cottin
et al., CPFE is characterized by a history of heavy smoking, exer
cise hypoxemia, upper lobe emphysema, lower lobe fibrosis,
abnormally low lung volumes, and severely reduced carbon monoxide transfer (7). Between 47% and 90% of patients with CPFE
develop PH (6, 8) and most will develop moderate to severe PH (9).
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PH contributes to the dysfunction of patients with CPFE including
severe dyspnea, markedly impaired transfer of gas, and exercise
hypoxemia, ultimately resulting in a poorer prognosis (10). An
estimated 1-year survival rate of 60% was reported in patients
with both CPFE and PH (8).
PH is characterized by pathologic changes in endothelial cell
(EC) and vascular wall function. In response to pathologic stimuli such as hypoxia, hyperplasia of vascular smooth muscle (VSM)
increases pulmonary vascular pressure (11–15). EC dysfunction,
excessive vascular remodeling, and inflammation contribute to
progressive elevation of pulmonary vascular resistance, leading to
increased right ventricular (RV) afterload. The histopathology of
PH is well documented, but the molecular mechanisms underlying the vascular remodeling are poorly understood.
Sustained increase in RV afterload ultimately results in right
heart failure. Current pharmacological treatments focused on
vasodilation for symptomatic relief have limited effects on vascular remodeling. Research has led to drugs that have significantly
decreased morbidity and prolonged life expectancy in patients
with Group 1 PH. Only some of these drugs show benefit to
patients with Group 3 PH (6, 16, 17). A mechanistic understanding
of the pulmonary vascular remodeling in Group 3 PH is thus necessary to identify noninvasive diagnostic tools for early detection
of cardiopulmonary compromise, to develop effective therapies,
to monitor treatment response, and to improve overall outcome.
Endothelial-mesenchymal transition (EndMT) is a form of
cellular plasticity described as the ability of ECs to dedifferentiate
into a multipotent mesenchymal progenitor. EndMT begins with a
morphological change from a classical cobblestone-like structure
1
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to an elongated, spindle shape. The process further undergoes a
loss of cell-cell adhesion, dissociation from the basement membrane, and migration into the medial layer. EndMT is involved in
normal vascular development and several pathologies, including
pulmonary arterial hypertension (PAH, also known as Group 1
PH), atherosclerosis, and tumor angiogenesis (18–20). EndMT
is regulated by a common set of physiological effectors, including hypoxia, inflammation, and shear stress (21), and molecular
effectors, including transforming growth factor β (TGF-β) and
fibroblast growth factor (FGF) (19). Inflammation facilitates
EndMT in a TGF-β–dependent manner (11), and shear stress
downregulates FGF receptor (FGFR) signaling and enhances
nuclear localization of TGF-β–activated Smad2/3 (21). EndMT is
characterized by reduced production of EC proteins such as platelet EC adhesion molecule-1 (PECAM1, CD31) and vascular endothelial cadherin (VE-cadherin, CDH5), accompanied by a concomitant increase in production of mesenchymal markers such
as α-smooth muscle actin (αSMA, ACTA2), fibronectin (FN1), and
vimentin (VIM) (22).
The TGF-β family consists of a group of multifunctional cytokines that signal via type 1 and type 2 Ser/Thr kinase receptors and
Smad transcription factors (23). Upon TGF-β activation, receptorregulated Smad2 and Smad3 become phosphorylated, translocate to the nucleus, and in combination with other transcription
factors regulate gene expression. TGF-β–induced phosphorylatedSmad2/3 (p-Smad2/3) nuclear accumulation is enhanced by
hypoxic conditions (24). TGF-β2 stimulates EndMT by signaling through canonical Smad2/3 and noncanonical pathways (18).
Activation of the Smad2/3 pathway leads to overexpression of
Twist (TWIST1 and TWIST2), Snail (SNAI1), and Slug (SNAI2)
transcription factors (25–27). The TWIST family are a group of
helix-loop-helix transcription factors that can bind DNA E-boxes
to regulate transcription (28). Among the EndMT target genes
upregulated by hypoxia, SNAI1 was identified as a master regulator (29). The SNAI1 family of zinc finger transcription factors
share a highly conserved C-terminal region required for transcriptional repressor activity and a posttranslationally modifiable central domain that can regulate protein stability or localization (30).
TGF-β–mediated EndMT can also be modulated by FGF signaling
through FGFRs and the adaptor molecule FRS2. Knocking down
FRS2 in human umbilical vein endothelial cells (HUVECs) caused
an increase in the production of αSMA and vimentin (31). Independent of TGF-β, loss of BMPR2 can also induce gene expression
changes consistent with EndMT (32). TGF-β has been shown to
induce EndMT in PAH (20); however, its role in Group 3 PH has
not been established.
FGF2 and FGFR1/2 protein levels are elevated in lung tissue
samples from patients with PH (33–35). Additionally, FGF2 is elevated in a mouse model of Group 3 PH where mice are exposed to
chronic hypoxia (36, 37) and in vitro in human ECs cultured under
hypoxic conditions (38). Changes in the expression of both ligand
and receptors suggest that there may be functional consequences
of this signaling pathway in the pathogenesis of PH. To study the
role of FGFR signaling in ECs in vivo, mouse models have been
generated that lack EC FGFR1 and FGFR2 (39, 40). Studies of
these mice show that EC FGFR1 and FGFR2 are dispensable for
mouse embryonic development and are not required for vascular
2

or hematopoietic homeostasis; however, when challenged with
skin, retina, or ischemia-reperfusion heart injury, mice lacking EC
FGFR1/2 displayed impaired neovascular growth and tissue repair
(39, 40). Additionally, loss of EC FGFR1 activity caused increased
neointimal thickness in a vein graft model (41). Studies investigating the role of FGFR signaling in EndMT have demonstrated interactions between FGFR and TGF-β signal transduction pathways
(42). Hence, we hypothesize that EC FGFR1/2 signaling promotes
EC signals that protect against PH.
To investigate the function of EC FGFR signaling in the
pathogenesis of PH, we examined the response of mice lacking
EC FGFR1/2 or mice in which EC FGFR1 signaling was activated
through 2 weeks of chronic hypoxia. We found that mice deficient
in EC FGFR signaling developed more severe PH, whereas mice
in which FGFR1 signaling was activated in ECs developed less
severe PH. Furthermore, we show that the lack of EC FGFR1/
2 signaling augmented EndMT changes in vivo and increased
TGF-β/Smad2/3 signaling. We found that activation of EC
FGFR1 signaling repressed EndMT. These studies establish
the importance of EC FGFR signaling in the pathogenesis of
hypoxia-induced PH and suggest the possibility of future FGF
pathway–based therapeutics aimed at reducing the severity of PH
in hypoxia-challenged patients.

Results

FGFR1 and FGFR2 inactivation in ECs worsens in vivo hypoxiaPH. To determine the effect of hypoxia on Fgf2 expression,
6-week-old mice were challenged with hypoxia (10% FiO2)
for 2 weeks. Quantitative real-time PCR (qRT-PCR) analysis of
whole lungs from mice exposed to 2 weeks of hypoxia or normoxia
showed increased expression of Fgf2 (Figure 1A). To ascertain
the requirements for FGF signaling in ECs in response to hypoxia, 6-week-old Flk1(Vegfr2/Kdr)Cre; Fgfr1fl/fl; Fgfr2fl/fl (FLK1-DCKO)
and Flk1Cre or Fgfr1fl/fl; Fgfr2fl/fl (control) mice were challenged with
hypoxia for 2 weeks. Cardiac catheterization was used to measure
RV pressure (RVp) as a surrogate for pulmonary arterial pressure.
Compared with control mice in normoxia, littermates in hypoxia
demonstrated significant increases in RVp (Figure 1B) and the RV
to left ventricle plus septum weight ratio (Figure 1, C and D), consistent with development of PH and RV hypertrophy, respectively. Hypoxia-exposed FLK1-DCKO mice (hFLK1-DCKO) showed
further elevation in RVp (by 24.4%, P < 0.05) (Figure 1B) and an
increased RV to left ventricle plus septum weight ratio as compared with controls (hControl; Figure 1, C and D), demonstrating
worsening PH in the absence of EC FGF signaling. Flk1Cre (a knockin mutation at the Vegfr2/Kdr locus) and wild-type mice under
normoxic conditions did not show any difference in RVp (Supplemental Figure 1A; supplemental material available online
with this article; https://doi.org/10.1172/JCI141467DS1). Hypoxia-challenged Flk1Cre and wild-type mice also did not show any
difference in RVp (Supplemental Figure 1B).
The echocardiographic imaging marker, pulmonary artery
acceleration time (PAAT), has been validated for detection of
pulmonary vascular disease and PH in mice (43). Comparison
of echocardiographic and cardiac catheterization measures
showed a strong correlation of PAAT (Figure 1E) and PAAT normalized to RV ejection time (PAAT/RVET) (Figure 1F) with RVp
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Figure 1. Increased severity of pulmonary
hypertension in mice lacking endothelial
FGFR1 and FGFR2. Pulmonary hypertension
assessment after 2 weeks of hypoxia exposure (white column) compared with normoxia controls (gray column). (A) Quantitative
RT-PCR showing Fgf2 expression in whole
lungs from wild-type mice, n = 4. Statistical
significance was determined by 2-tailed,
unpaired Student’s t test. (B) RV pressures
determined by cardiac catheterization of
hypoxia-challenged control (Flk1Cre or Fgfr1fl/fl;
Fgfr2fl/fl) and FLK1-DCKO mice compared with
littermates in normoxia, n = 7–13. (C) RV to
left ventricular plus septal (RV/LV+S)
weight comparison between hypoxiaexposed control and FLK1-DCKO mice
compared with littermates in normoxia, n =
4–6. (D) Representative specimens of whole
hearts. Scale bar: 10 mm. (E) Correlation plot
of right heart catheterization–derived pulmonary hemodynamics and pulmonary artery
acceleration time (PAAT) from all mice
(normoxia and hypoxia), n = 26. (F) Correlation plot of right heart catheterization–
derived pulmonary hemodynamics and PAAT/
RV ejection time ratio (PAAT/RVET), n = 26.
(G and H) Comparison of PAAT (G) and PAAT/
RVET (H) in hypoxia-challenged FLK1-DCKO
and control mice, n = 4–10. Statistical significance was determined by 2-way ANOVA
with Holm-Šídák multiple comparison test.
All data are shown as the mean ± SEM. *P <
0.05, **P < 0.01. Closed circles, control mice
in normoxia (nControl); open circles, control
mice in hypoxia (hControl); closed squares,
FLK1-DCKO mice in normoxia (nFLK1-DCKO);
open squares, FLK1-DCKO mice in hypoxia
(hFLK1-DCKO).

in hypoxia-challenged mice. PAAT was decreased in control
hypoxia-exposed mice compared with normoxia controls and
FLK1-DCKO mice showed a further decrease when compared
with control mice in hypoxia (Figure 1G). The PAAT/RVET
ratio showed a significant decrease in hypoxia compared with
normoxia-exposed mice and FLK1-DCKO mice showed a further decrease in these measures after 2 weeks in hypoxia (Figure 1H). Therefore, loss of EC FGFR signaling is sufficient to
increase hypoxia-induced PH.
Histologic analyses of the pulmonary arteries showed
increased medial thickening in control mice in hypoxia as compared with littermates in normoxia (Figure 2A). Compared with

control mice in normoxia, littermates in hypoxia demonstrated
significant increase in medial areas of both smaller caliber, distal vessels (20–50 μm, Figure 2B) and larger caliber, proximal
vessels (50–100 μm, Figure 2C). FLK1-DCKO mice showed
further increases in the vascular medial area as compared with
controls (Figure 2, A–C), demonstrating more severe pulmonary vascular remodeling. To assess neomuscularization, lung
tissue sections were coimmunostained with antibodies against
PECAM1 and αSMA to identify ECs and VSM, respectively.
Hypoxia reduced the proportion of nonmuscularized and partially muscularized vessels and increased the proportion of
fully muscularized vessels as compared with normoxia controls
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Figure 2. Histologic analysis of the pulmonary vasculature in mice lacking endothelial FGFR1 and
FGFR2. (A) Smooth muscle actin (αSMA) immunostaining of representative lungs from control and
FLK1-DCKO mice in normoxia and hypoxia. Scale bars: 1 mm and 50 μm (insets). (B and C) Vessel wall
thickening as assessed by medial cross-sectional area normalized to total vessel cross-sectional area
(medial/CSA) for (B) distal vessels (20–50 μm) and (C) proximal vessels (50–100 μm), n = 4–5. (D)
Quantification of the percentage of muscularized vessels compared with total number of vessels, in
normoxia- and hypoxia-exposed control and FLK1-DCKO mice, n = 4–5. Statistical significance was
determined by 2-way ANOVA with Holm-Šídák multiple comparison test. All data are shown as the
mean ± SEM. *P < 0.05, **P < 0.01. Closed circles, control mice in normoxia (nControl); open circles,
control mice in hypoxia (hControl); closed squares, FLK1-DCKO mice in normoxia (nFLK1-DCKO); open
squares, FLK1-DCKO mice in hypoxia (hFLK1-DCKO).
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(Figure 2D). FLK1-DCKO mice showed a
further increase in the proportion of fully
muscularized vessels when compared with
control littermates in hypoxia (Figure 2D).
Thus, loss of EC FGFR signaling augments
vascular changes associated with hypoxiainduced PH.
To rule out potential developmental
effects due to constitutive loss of EC Fgfr1
and Fgfr2 and heterozygosity of Vegfr2
(Flk1Cre) on PH pathology, the conditional
Cdh5-CreERT2 transgenic allele was used
to inactivate Fgfr1 and Fgfr2 and activate the
ROSAtdTomato lineage reporter in ECs of juvenile mice. Three-week-old Cdh5-CreERT2;
Fgfr1fl/fl; Fgfr2fl/fl; ROSAtdTomato (Cdh5-DCKO)
and control Fgfr1fl/fl; Fgfr2fl/fl (control) mice
were treated with tamoxifen from 3–4
weeks of age (Figure 3A). Lineage analysis
showed colabeling of PECAM1 and tdTomato fluorescence, confirming EC targeting by tamoxifen-treated Cdh5-CreERT2;
ROSAtdTomato mice (Figure 3B). Transcriptional analysis of pulmonary ECs isolated
from mouse lungs using flow cytometry
showed that Fgfr1 (Figure 3C) and Fgfr2
(Figure 3D) expression was significantly
decreased. Cdh5-DCKO mice were challenged with hypoxia for 2 weeks, followed
by cardiac catheterization to measure RVp.
Compared with control mice exposed to
hypoxia, Cdh5-DCKO mice demonstrated
significant increases in RVp (by 13.2%, P <
0.05) (Figure 3E). These results show that
loss of EC FGFR1 and FGFR2 beginning at 3
weeks of age worsens hypoxia-induced PH,
similar to FLK1-DCKO mice.
FGFR1 activation in ECs prevents hypoxiainduced PH. Because loss of EC Fgfr1 and
Fgfr2 leads to VSM thickening in response to
hypoxia, we hypothesized that expression of
a constitutively active FGFR1 (caFGFR1) in
ECs would protect against maladaptive vessel muscularization in hypoxia-induced PH.
To investigate the cell-autonomous function
of FGF signaling in ECs, we utilized the
Tie2-Cre transgenic allele to target the doxycycline-inducible TET-on Cre-regulatable
ROSArtTA allele, and a chimeric constitutively
active Fgfr1 transgenic allele (TRE-caFgfr1)
in ECs. We generated Tie2-Cre; ROSArtTA;
TRE-caFgfr1 (caFGFR1) triple-transgenic
mice (Figure 4A) to conditionally activate
EC FGFR signaling. Doxycycline treatment, starting at 4 weeks of age for 2 weeks,
increased caFGFR1 expression in lungs of
caFGFR1 compared with control mice (Fig-
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Figure 3. Effects of conditional deletion of Fgfr1
and Fgfr2 in endothelial cells on hypoxia-induced
pulmonary hypertension. (A) Experimental strategy for tamoxifen-induced Cdh5-targeted deletion
of Fgfr1 and Fgfr2 in endothelial cells (ECs). (B)
Tamoxifen-induced Cdh5-targeted tdTomato (red)
expression in ECs (PECAM1, green, arrowheads).
Scale bars: 25 μm and 20 μm (insets). (C and D)
Quantitative RT-PCR showing reduction of Fgfr1
and Fgfr2 expression in pulmonary ECs of tamoxifen-treated (Cdh5-DCKO) mice compared with
control littermates, n = 5–6. Statistical significance
was determined by 2-tailed, unpaired Student’s
t test. (E) RV pressures determined by cardiac
catheterization of hypoxia-challenged control and
Cdh5-DCKO mice, n = 7–17. Statistical significance
was determined by 2-way ANOVA with Holm-Šídák
multiple comparison test. All data are shown as the
mean ± SEM. *P < 0.01, **P < 0.05. Closed circles,
control mice in normoxia (nControl); open circles,
control mice in hypoxia (hControl); closed squares,
Cdh5-DCKO mice in normoxia (nCdh5-DCKO); open
squares, Cdh5-DCKO mice in hypoxia (hCdh5-DCKO).

ure 4B). In prior studies, induction of caFGFR1 in ECs for 1 month
did not have any apparent adverse effects (44).
Four-week-old caFGFR1 and control mice were placed on doxycycline chow. Starting at 6 weeks of age, mice were challenged
with hypoxia for 2 weeks, followed by cardiac catheterization to
measure RVp. In response to hypoxia, control mice demonstrated
significant increases in RVp (Figure 4C) and the RV to left ventricle plus septum weight ratio (Figure 4, D and E), consistent with
development of PH. At baseline, caFGFR1 mice compared with
control mice in normoxia showed no difference in RVp (Figure 4C)
and the RV to left ventricle plus septum weight ratio (Figure 4D).
However, in response to hypoxia, caFGFR1 mice showed similar
RVp and RV to left ventricle plus septum weight ratio compared
to normoxia mice, and significantly lowered RVp (by 23.7%, P <
0.05) and RV to left ventricle plus septum weight ratio compared
with hypoxia-exposed control mice (Figure 4, C and D). Therefore, activation of EC FGFR1 signaling is sufficient to prevent
hypoxia-induced PH.
Effects of hypoxia on the pulmonary vasculature of caFGFR1
mice were consistent with resistance to the development of PH
(Figure 5A). In normoxia, caFGFR1 mice and control mice showed
no difference in the medial area of both smaller caliber distal vessels (20–50 μm, Figure 5B) and larger caliber proximal vessels
(50–100 μm, Figure 5C). In response to hypoxia, control mice
demonstrated significant increases in the medial area of both
large and small caliber vessels (Figure 5, B and C). However, in
response to hypoxia, caFGFR1 mice showed similar medial areas
of small caliber vessels to those of mice in normoxia and no difference in the medial area of smaller caliber vessels in caFGFR1 mice
in hypoxia versus normoxia (Figure 5B). The medial area of large

caliber vessels was modestly increased (1.6-fold) when comparing
caFGFR1 mice in hypoxia versus normoxia; however, the medial
area of large caliber vessels was still much reduced compared with
control mice in hypoxia (4.0-fold) (Figure 5C).
To assess neomuscularization, lung tissue sections were
coimmunostained for PECAM1 and αSMA to identify ECs and
VSM cells, respectively. In normoxia, caFGFR1 and control mice
showed no difference in the proportions of nonmuscularized,
partially muscularized, and fully muscularized vessels (Figure
5D). In response to hypoxia, control mice demonstrated a significant reduction in the proportion of nonmuscularized and partially
muscularized vessels, and an increase in the proportion of fully
muscularized vessels (Figure 5D). However, in response to hypoxia, caFGFR1 mice showed similar proportions of vessel muscularization to those of mice in normoxia, and a significantly lower
proportion of fully muscularized vessels compared with hypoxiaexposed control mice (Figure 5D). These results demonstrate that
EC FGFR1 activity reduces histologic changes in the vasculature
associated with hypoxia-induced PH.
FGF signaling reduces hypoxia-induced EndMT. Reprograming
of ECs to VSM (Figure 6A), a process known as EndMT, underlies several disease pathologies (18–20). To evaluate the effect of
hypoxia on EndMT, Tie2-Cre; ROSAtdTomato EC-lineage reporter mice were exposed to hypoxia (Figure 6B). After 2 weeks in
hypoxia, VSM cells in the tunica media layer were found to express
the tdTomato EC-lineage tag (Figure 6B), indicating an EndMT
response to hypoxic conditions. Normoxia control mice showed
no tdTomato fluorescence in αSMA-positive cells. Hypoxiaexposed control mice were also coimmunostained for PECAM1 and
αSMA to demonstrate EndMT (Figure 6C). VSM cells in the medial
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Figure 4. Effects of cell-autonomous activation
of FGFR1 in endothelial cells on the development of hypoxia-induced pulmonary hypertension. (A) Experimental strategy for expressing
the tetracycline-inducible constitutively active
FGFR1 (caFGFR1) in endothelial cells (ECs).
Tie2-Cre; ROSArtTA results in reverse tetracyclinecontrolled transactivator (rtTA) expression in ECs
(blue arrow), and in the presence of doxycycline
(green box), TRE-caFGFR1 expression is induced
in ECs (TIE2-caFGFR1 = Tie2-Cre; ROSArtTA;
TRE-caFgfr1). (B) Quantitative RT-PCR showing
induction of caFGFR1 expression in lungs of doxycycline-treated compared with untreated mice,
n = 3–4. Statistical significance was determined
by 2-tailed, unpaired Student’s t test. (C) RV
pressures determined by cardiac catheterization
of hypoxia-challenged control and caFGFR1 mice,
n = 4–15. (D) Right ventricular to left ventricular plus septal (RV/LV+S) weight comparison
between control and caFGFR1 mice, n = 4. (E)
Representative whole hearts. Scale bar: 10 mm.
Statistical significance was determined by 2-way
ANOVA with Holm-Šídák multiple comparison
test. All data are shown as the mean ± SEM.
NS, not significant. *P < 0.05, **P < 0.01.
caFGFR1 = Tie2-Cre; ROSArtTA; TRE-caFgfr1.
Closed circles, control mice in normoxia
(nControl); open circles, control mice in hypoxia
(hControl); closed squares, TIE2-caFGFR1 mice in
normoxia (ncaFGFR1); open squares,
TIE2-caFGFR1 mice in hypoxia (hcaFGFR1).

layer expressed the endothelial marker PECAM1 (Figure 6C), further supporting an EndMT response to hypoxic conditions.
To determine whether loss of FGFR1 and FGFR2 signaling
in EC affects EndMT, Fgfr1fl/fl; Fgfr2fl/fl control and Flk1Cre; Fgfr1fl/fl;
Fgfr2fl/fl; ROSAtdTomato (FLK1-DCKO/Tomato) mice were examined.
In normoxia, control and FLK1-DCKO/Tomato mice did not show
any difference in the proportion of VSM cells with the tdTomato
EC-lineage tag (Figure 7A). In mice exposed to hypoxia, control
mice showed a significant increase in the percentage of EC lineage–tagged VSM cells compared with normoxia, and hypoxiaexposed FLK1-DCKO/Tomato mice demonstrated a further
increase in the percentage of VSM cells derived from the EC lineage (Figure 7A). To determine the effects of activation of FGFR1
signaling on EndMT, we used the caFGFR1 mouse model. Fourweek-old caFGFR1 and control mice were placed on doxycycline
chow. Starting at 6 weeks of age, mice were challenged with
hypoxia for 2 weeks. Under normoxic conditions, caFGFR1 and
control mice did not show any difference in the proportion of VSM
cells derived from the EC lineage (Figure 7B). Relative to mice in
normoxia, control mice exposed to hypoxia showed a significant
increase in the percentage of VSM cells derived from the EC lineage. Compared with control mice in hypoxia, caFGFR1 mice in
hypoxia showed a significant reduction in EndMT (Figure 7B),
indicating that activation of FGFR1 in ECs inhibits EndMT.
FLK1-DCKO/Tomato and Fgfr1fl/fl; Fgfr2fl/fl control mice
were also coimmunostained for PECAM1 and αSMA to demonstrate EndMT. In normoxia, FLK1-DCKO mice did not show any
6

difference in the proportion of VSM cells expressing PECAM1
(Figure 7C). In mice exposed to hypoxia, control mice showed
a significant increase in the percentage of PECAM1-expressing VSM cells compared with normoxia, and hypoxia-exposed
FLK1-DCKO demonstrated a further increase in the percentage
of VSM cells expressing the EC marker, PECAM1 (Figure 7C).
Under normoxic conditions, caFGFR1 and control mice did not
show any difference in the proportion of VSM cells expressing
PECAM1 (Figure 7D). Control mice exposed to hypoxia showed
a significant increase in the percentage of VSM cells expressing
PECAM1, compared with mice in normoxia. Relative to control
mice in hypoxia, caFGFR1 mice in hypoxia showed a significant
reduction in EndMT (Figure 7D), further demonstrating that EC
FGFR1 activation inhibits EndMT.
FGF signaling inhibits the TGF-β pathway response to hypoxia
in vivo. TGF-β signaling regulates EndMT in Group 1 PAH and
atherosclerosis (20, 45). To evaluate the effect of EC Fgfr1 and
Fgfr2 deletion on TGF-β signaling, qRT-PCR analysis was performed on RNA from whole lungs of FLK1-DCKO and control
mice exposed to 2 weeks of hypoxia or normoxia. In normoxia,
FLK1-DCKO mice did not show any differences in expression of
TGF-β pathway components compared to controls (Figure 8A).
FLK1-DCKO mice in hypoxia demonstrated increased expression of Tgfbr2, Snai1, Snai2, Twist1, and Acta2 and decreased
expression of Pecam1 (Figure 8A). Tgfb1 and Tgfb2 ligand expression was decreased in hypoxia-exposed FLK1-DCKO mice compared with controls (Supplemental Figure 2). FLK1-DCKO mice
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Figure 5. Constitutively active FGFR1 reduces the pulmonary vascular
response to hypoxia. (A) Smooth muscle actin (αSMA) immunostaining of representative lungs from control and caFGFR1 mice in normoxia
and hypoxia. Scale bars: 1 mm and 50 μm (insets). (B and C) Vessel wall
thickening as assessed by medial cross-sectional area normalized to total
vessel cross-sectional area (medial/CSA) for (B) distal vessels (20–50
μm) and (C) proximal vessels (50–100 μm), n = 4. (D) Quantification of the
percentage of muscularized vessels compared with total number of vessels, in normoxia- and hypoxia-exposed control and caFGFR1 mice, n = 4.
Statistical significance was determined by 2-way ANOVA with Holm-Šídák
multiple comparison test. All data are shown as the mean ± SEM. NS, not
significant. *P < 0.05, **P < 0.01. caFGFR1 was induced as shown in Figure
4A. Closed circles, control mice in normoxia (nControl); open circles, control
mice in hypoxia (hControl); closed squares, TIE2-caFGFR1 mice in normoxia
(ncaFGFR1); open squares, caFGFR1 mice in hypoxia (hcaFGFR1).

in normoxia also did not show any differences in the expression of Fgf2 (Figure 8A). In hypoxia, control mice demonstrated
increased Fgf2 and hypoxia-exposed FLK1-DCKO mice showed a
further increase in Fgf2 expression.
To evaluate the effect of activation of FGFR1 signaling in
ECs, qRT-PCR analysis was performed on RNA from whole lungs

of caFGFR1 and control mice that were exposed to 2 weeks of
hypoxia or normoxia. In normoxia, there was no difference in the
expression of TGF-β pathway components in caFGFR1 and control mice (Figure 8B). In hypoxia, control mice showed increased
expression of Tgfbr2, Snai1, Snai2, and Fgf2, while Twist1, Pecam1,
and Acta2 expression was not changed. However, in hypoxia, compared with controls, caFGFR1 mice showed lower levels of Tgfbr2,
Snai1, Snai2, Twist1, and Fgf2, and similar levels of Pecam1 and
Acta2. Tgfb1 and Tgfb2 ligand expression was decreased in hypoxiaexposed caFGFR1 mice compared with controls (Supplemental
Figure 2). Notably, caFGFR1 mice in normoxia did not show any
differences in expression of Fgf2, whereas control mice in hypoxia
showed significantly higher levels of Fgf2 (Figure 8B).
To directly assess TGF-β signaling in vivo, we immunostained
lung tissue for p-Smad2/3 in both mouse models. In control lungs,
hypoxia exposure increased p-Smad2/3 compared with normoxia
(Figure 9). Under hypoxic conditions, FLK1-DCKO mice showed
a further increase in the percentage of p-Smad2/3–expressing
ECs compared with control mice (Figure 9A) and caFGFR1 mice
showed less p-Smad2/3 expression in ECs (Figure 9B). These
results demonstrate that FGF signaling suppresses TGF-β signaling and EndMT in response to hypoxia.
FGF inhibition promotes EndMT in vitro. To directly assess
the effects of FGF inhibition on EndMT, human pulmonary
artery ECs (HPAECs) were cultured in hypoxia (5% O2) for 48
hours (Figure 10A) or 14 days (Figure 10B), and then assayed for
changes in RNA expression of TGF-β pathway components and
markers of EndMT. After 48 hours, treatment with the FGF inhibitor BGJ398 (infigratinib) under normoxic conditions increased
Tgfb2 21-fold, increased Acta2 and Fgf2, and decreased Cdh5,
but did not change the expression of the transcription factors
Snai2 and Twist1 and the mesenchymal marker Vim. FGF inhibition under hypoxic conditions increased Tgfb2 (40-fold), Snai2,
and Twist1, and decreased Cdh5. Expression of Acta2 and Fgf2
trended toward an increase.
HPAECs were then cultured for 14 days to evaluate the effects
of chronic hypoxia and FGF inhibition on EndMT in vitro (Figure
10B). In normoxia, FGF inhibition with BGJ398 did not exert any
significant effects on expression of Tgfb2, Snai2, Twist1, Cdh5, or
Vim, whereas expression of Fgf2 was increased and Acta2 trended
toward an increase. However, when cultured in hypoxia,
BGJ398-treated HPAECs demonstrated increased expression of
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Figure 6. FGFR signaling regulates endothelial-mesenchymal transition in
hypoxia-induced pulmonary hypertension. (A) Illustration depicting the process
of endothelial-mesenchymal transition (EndMT). (B) Lineage tracing visualized by
immunostaining smooth muscle cells (αSMA, green) expressing endothelial origins
(Tie2-Cre; ROSAtdTomato, red) after 2 weeks of hypoxia. Scale bars: 25 μm and 15 μm
(insets). Inset, higher magnification image illustrating overlay of αSMA (green) and
endothelial lineage tdTomato (red). (C) Lineage tracing visualized by immunostaining
smooth muscle cells (αSMA, green) expressing endothelial origins (PECAM1,
red) after 2 weeks of hypoxia. Scale bars: 25 μm and 15 μm (insets). Inset, higher
magnification image illustrating overlay of αSMA (green) and PECAM1 (red). Arrows,
non–endothelial origin smooth muscle cells; arrowheads, endothelium-originated
smooth muscle cells.

Tgfb2, Twist1, and Acta2, a trend toward increased expression of
Snai2 and Fgf2, and decreased expression of Cdh5 (Figure 10B).
Notably, chronic hypoxia increased expression of Fgf2 and downstream transcriptional targets of FGF signaling, ETS transcription
variant 4 and 5 (Etv4 and Etv5), and dual-specificity phosphatase 6
(Dusp6) (Figure 10, B and C). As expected, expression of Etv4 was
decreased with FGFR inhibition (Supplemental Figure 4).
Compared with normoxia, exposure to 5% oxygen for 14
days did not induce expression of αSMA in HPAECs (Figure 11A).
However, HPAECs exposed to 5% oxygen for 14 days and treated
with BGJ398 formed colonies of αSMA-expressing cells, demon8

strating EndMT in vitro (Figure 11A). Quantitative analyses showed an increased number of colonies of αSMApositive cells per well in BGJ398-treated hypoxia-exposed
HPAECs, and no colonies in untreated or normoxiacultured wells (Figure 11B). Western blot analysis showed
no difference in Smad2/3 phosphorylation or ACTA2
expression in normoxia. BGJ398 treatment increased
Smad2/3 phosphorylation and αSMA expression in
hypoxia-exposed HPAECs (Figure 11, C and D). These
data demonstrate that, in response to hypoxia, EndMT
activity and TGF-β signaling are increased when FGF signaling is inhibited (Figure 11, D and E).
EndMT observed in patients with CPFE and PH. Group
3 PH can be caused by hypoxia resulting from lung disorders such as COPD, BPD, or CPFE (1, 2). To evaluate
the presence of molecules known to mediate EndMT in
CPFE, we assessed histological sections of lungs from
patients with CPFE in comparison with normal lung
tissue. Patients with CPFE had average mean pulmonary artery pressure of 31 mmHg (Supplemental Table
1), above the diagnostic criteria of 25 mmHg for PH. To
assess FGF and TGF-β signaling, we examined expression of ETV5 and p-Smad2/3, respectively. Compared
with controls, lung tissue sections from patients with
CPFE showed decreased immunostaining for ETV5 (Figure 12A). In normal lung tissue, an average of 95% of
CDH5-positive ECs were positive for ETV5, compared
with 73% in CPFE lung tissue (Figure 12C). Immunostaining for p-Smad2/3 showed increased expression
in CPFE lung tissue compared with normal lung tissue
(Figure 12B). In normal lung tissue, an average of 50% of
CDH5-positive ECs were positive for p-Smad2/3, compared with 64% of CDH5-positive ECs that were positive
for p-Smad2/3 in CPFE lung tissue (Figure 12D). These
data correlate pulmonary pathologies such as CPFE that
contribute to Group 3 PH with reduced FGF signaling and
increased TGF-β signaling, similarly to experimental conditions that promote EndMT such as chronic hypoxia.

Discussion

The results of this study support a role for EC FGFR
signaling as a modulator of the EndMT response in the
pathogenesis of hypoxia-induced PH. We showed that
in response to chronic hypoxia, (a) loss of EC FGFR1 and
FGFR2 signaling increased PH, (b) activation of FGFR1
in ECs prevented PH, (c) EC FGFR signaling attenuated
the TGF-β signaling pathway, and (d) FGFR signaling was reduced
and TGF-β signaling was activated in lung tissue from patients
with CPFE. Taken together, these results establish a link between
hypoxia, the loss of protective EC FGFR signaling input, and the
induction of EndMT, which ultimately plays an important role in
the pathogenesis of hypoxia-induced PH.
FGFR1 is robustly expressed, while FGFR2 and -3 are
expressed at lower levels in normal ECs (40, 41, 46–48). Under
homeostatic conditions, inactivation of EC Fgfr1 and Fgfr2 did
not cause any overt developmental or homeostatic defects.
However, several studies showed that loss or inhibition of these
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required under homeostatic conditions (39, 40). By
contrast, under hypoxic conditions, FLK1-DCKO mice
demonstrated increased vessel wall thickness and neovascularization when compared with their littermate
controls. These results show that loss of EC FGFR
signaling promotes changes that are associated with
hypoxia-induced PH.
The Flk1Cre mouse is heterozygous for Vegfr2
(Kdr). Haploinsufficiency of Vegfr2 suppresses tumorinduced angiogenesis (52) and leads to increased
infarct size in a myocardial ischemia-reperfusion injury model (53). Additionally, pharmacological inhibition
of VEGFR is an important regulator of PH (54), and
mice treated with the VEGFR inhibitor SU5416 exhibited PH changes in response to hypoxia (55, 56). Furthermore, mice heterozygous for Vegfr2 show reduced
pathological angiogenesis (57, 58). It was therefore
important to assess the effects of Vegfr2 haploinsufficiency on hypoxia-induced PH. Although VEGFR2
activity is vital to vascular development (59), we did
not observe any identifiable physiologic or histologic phenotypes in Flk1Cre and wild-type mice under
normoxic conditions. Furthermore, we found no difference between wild-type, Flk1Cre, and FGFR1fl/fl;
FGFR2fl/fl mice after challenge with hypoxia.
To rule out potential developmental and Vegfr2
Figure 7. FGFR signaling regulates endothelial-mesenchymal transition in hypoxiahaploinsufficiency effects on the phenotype of FLK1induced pulmonary hypertension. Quantification of EndMT shown as a percentage
DCKO mice, we constructed Cdh5-DCKO mice as a
of tdTomato+αSMA+ double-positive cells in relation to the total number of αSMA+
second model to inducibly inactivate Fgfr1 and Fgfr2 in
cells in (A) FLK1-DCKO mice (n = 4–6) and (B) caFGFR1 mice (n = 4–7). Quantification of
+
+
ECs in juvenile mice. Cdh5-DCKO mice did not show
EndMT shown as a percentage of PECAM1 αSMA double-positive cells in relation to
the total number of αSMA+ cells in (C) FLK1-DCKO mice (n = 3) and (D) caFGFR1 mice
any apparent developmental or homeostatic defects
(n = 3–4). Statistical significance was determined by 2-way ANOVA with Holm-Šídák
under normoxic conditions. However, Cdh5-DCKO
multiple comparison test. All data are shown as the mean ± SEM. **P < 0.01. Closed
mice demonstrated worse PH when exposed to hypoxcircles, control mice in normoxia (nControl); open circles, control mice in hypoxia
ia, similar to but less severe than what was observed in
Cre
fl/fl
fl/fl
(hControl); closed squares, Flk1 ; Fgfr1 ; Fgfr2 mice in normoxia (nFLK1-DCKO) or
Cre
fl/fl
fl/fl
FLK1-DCKO mice. These findings further support the
caFGFR1 mice in normoxia (ncaFGFR1); open squares, Flk1 ; Fgfr1 ; Fgfr2 mice in
hypoxia (hFLK1-DCKO) or caFGFR1 mice in hypoxia (hcaFGFR1).
model that EC FGFR signaling in adult mice worsens
hypoxia-induced PH.
To test whether activation of EC FGFR signalreceptors in ECs leads to defective injury responses (39–41, 49).
ing could protect against hypoxia-induced PH, we induced the
Based on these observations, we hypothesized that EC FGFR
expression of a chimeric constitutively active FGFR1 (caFGFR1)
signaling would be protective against the adaptive vascular
in ECs before and during exposure to hypoxia. Previously, we
response to hypoxia. To test this, two models were used to inacshowed that caFGFR1 overexpression led to increased exprestivate floxed alleles of Fgfr1 and Fgfr2 in ECs: constitutive tarsion of downstream FGFR1 target signals and genes (44, 60,
geting with Flk1Cre (FLK1-DCKO) and inducible targeting with
61). Here, we showed that with caFGFR1 induced in ECs, the
average RVp and RV hypertrophy of caFGFR1 mice were sigCdh5-CreER (Cdh5-DCKO).
nificantly lower than control littermates in hypoxia. In fact, the
Group 3 PH can be modeled by placing mice in normobaraverage RVp of the caFGFR1 group was comparable to that of
ic chambers at 10% effective oxygen, which results in a reliable
normoxia controls. Additionally, histologic changes were limincrease in RVp by at least 10 mmHg, RV hypertrophy, and pulited to a moderate increase in VSM thickening of proximal,
monary vascular remodeling (50). Additionally, after exposing
larger caliber vessels. Although Tie2 also targets hematopoietic
6-week-old mice to 10 days of hypoxia, pulmonary artery vescell lineages, we did not observe any physiologic differences
sel wall thickness was increased (51). To assess the in vivo role
between control and caFGFR1 mice under normoxic condiof FGFR signaling in the development of PH, we investigated
tions. As caFGFR1 expression was induced 2 weeks prior to and
the effect of loss of FGFR signaling in mice with experimental
throughout the duration of hypoxia exposure, the absence of
PH induced by hypoxia. Under normoxic conditions, inactivaPH changes may, in part, be due to a preventive effect. To detertion of EC FGFR1/2 signaling with Flk1Cre (FLK1-DCKO) did not
mine whether there may be a therapeutic effect of activated
result in any identifiable physiologic or histologic phenotypes,
EC FGFR signaling, future studies will be required in which
consistent with previous findings that EC FGFR signaling is not
J Clin Invest. 2021;131(17):e141467 https://doi.org/10.1172/JCI141467
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Figure 8. Effect of hypoxia and
FGFR signaling on expression of
the TGF-β–mediated endothelial-mesenchymal transition
pathway. RNA expression of
components of the TGF-β pathway during EndMT in lungs of
hypoxia-exposed (A) FLK1-DCKO
(n = 4) and (B) caFGFR1 mice (n
= 4). Statistical significance was
determined by 2-way ANOVA
with Holm-Šídák multiple comparison test. All data are shown
as the mean ± SEM. *P < 0.05,
**P < 0.01. Closed circles, control
mice in normoxia (nControl); open
circles, control mice in hypoxia
(hControl); closed squares, Flk1Cre;
Fgfr1fl/fl; Fgfr2fl/fl mice in normoxia
(nFLK1-DCKO) or caFGFR1 mice
in normoxia (ncaFGFR1); open
squares, Flk1Cre; Fgfr1fl/fl; Fgfr2fl/fl
mice in hypoxia (hFLK1-DCKO)
or caFGFR1 mice in hypoxia
(hcaFGFR1).

caFGFR1 expression is induced at different time points after
the initiation of hypoxia exposure.
We and others have reported that EC FGFR1 and FGFR2 are
not necessary for vascular development or homeostasis, including the maintenance of normal vascular barrier function (39, 40,
41). Collectively, these studies suggest that under homeostatic
conditions ECs are resistant to gain or loss of FGFR1/2 signaling.
Further studies will be required to understand the basis of this
resistance and how perturbations of homeostasis, such as injury
or hypoxia, sensitize ECs to FGFR signaling. The absence of an
effect of FGFR activation on unperturbed ECs also suggests that
the EC FGFR1 signaling pathway may be a safe therapeutic target
for the prevention of hypoxia-induced PH.
10

In contrast to the results in this study, Chang et al. showed that
mice expressing perlecan that is deficient in heparan sulfate (HS),
a cofactor for FGF-FGFR binding, have reduced PH in response to
hypoxia (37). Although these mice may have reduced FGF signaling, several factors may account for their contrasting response to
hypoxia. First, perlecan-HS may affect the activity of other growth
factors in addition to FGF. For example, perlecan is required for
VEGF signaling in skeletal angiogenesis, developmental angiogenesis, and VEGFR2 activation of human ECs (62, 63). Second,
perlecan-HS–deficient mice have developmental defects that
include a reduced percentage of αSMA-positive pulmonary vessels
and reduced pericyte coverage of distal pulmonary vessels, which
is in contrast with our EC-targeted FGFRs that have no change in
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against hypoxia-induced PH. Fate
mapping with reporter mice has
facilitated the discovery of EndMT
in many disease models. Qiao et al.
found high levels of EC-lineage cells
expressing αSMA and smooth muscle myosin heavy chain in remodeled pulmonary arteries of mice
with PH (65). In the mouse models
presented here, loss of EC FGFR signaling in vivo together with hypoxia
exposure resulted in an increase in
the number of smooth muscle cells
of endothelial origin. Conversely,
activation of FGFR signaling in
ECs decreased the contribution of
endothelium-originated cells to the
smooth muscle layer, suggesting that
FGFR signaling inhibits the EndMT
process. Some of the EndMT processes include loss of EC cell-cell
contact, increased expression of
Twist1, Snai1, Snai2, and Acta2, and
decreased expression of Cdh5 and
Pecam1 (19, 20, 66). Hence, we show
that exposing our mice to hypoxia
increased expression Tgfbr2 in vivo
along with EndMT mediators Snai1,
Snai2, and Twist1. We found that
lack of EC FGFR signaling further
augmented EndMT changes, and
increased EC FGFR1 activity inhibited this process. FGF2 can modulate TGF-β1 signaling by regulating ALK5 and TGF-βR2 expression
(67) and TWIST1 further enhances
Figure 9. p-Smad2/3 expression in pulmonary endothelial cells. (A and B) Visualization of p-Smad2/3
(red) and endothelial cell (PECAM1, green) immunofluorescence. Arrowheads, p-Smad2/3+PECAM1+ doubleTGF-βR2 expression and Smad2
positive endothelial cells; arrows, PECAM1+ singly positive endothelial cells. Scale bars: 25 μm and 20 μm
phosphorylation,
resulting
in
(insets). Quantification of EndMT (right) showing the percentage p-SMAD2/3+PECAM1+ double-positive
decreased
expression
of
EC
markendothelial cells as a percentage of all PECAM1+ endothelial cells in (A) FLK1-DCKO and (B) caFGFR1 mouse
ers (66, 68). Chen et al. also showed
lungs, respectively, n = 4. Statistical significance was determined by 2-way ANOVA with Holm-Šídák
that inhibition of FGF signaling
multiple comparison test. All data are shown as the mean ± SEM. **P < 0.01. Closed circles, control mice in
normoxia (nControl); open circles, control mice in hypoxia (hControl); closed squares, Flk1Cre; Fgfr1fl/fl; Fgfr2fl/fl
with a dominant negative mutant of
mice in normoxia (nFLK1-DCKO) or caFGFR1 mice in normoxia (ncaFGFR1); open squares, Flk1Cre; Fgfr1fl/fl;
FGFR1 or FRS2α increased TGF-β
Fgfr2fl/fl mice in hypoxia (hFLK1-DCKO) or caFGFR1 mice in hypoxia (hcaFGFR1).
signaling (41). Hence, we asked
whether EC FGFR activity modulates TGF-β signaling in hypoxiavascular wall thickening or neovascularization under normoxic
exposed mice. We demonstrated that loss of EC FGFR and hypoxia
conditions. Third, Chang et al. exposed female mice to 4 weeks
exposure increased Tgfbr2 expression and downstream Twist1
of hypoxia, whereas we exposed male mice to 2 weeks of hypoxexpression. Consistent with these results, we showed that Tgfbr2
ia, and we found a sex-specific difference in RVp when comparing
expression was reduced when FGFR signaling was activated in
male and female mice, with male mice showing lower RVp comthe presence of hypoxia, resulting in decreased Smad2/3 phospared with female mice (Supplemental Figure 3).
phorylation. However, because FRS2 is also a critical regulator
EndMT is an adaptive response that is involved in the pathoof VEGF signaling (69), further studies are warranted to detergenesis of several vascular diseases (21, 45, 64). Studies have
mine the relative contributions of VEGFR and FGFR signaling to
shown that FGF-regulated TGF-β signaling can modulate EndEndMT. Although the number of ECs expressing p-Smad2/3 in
MT in a mouse model of atherosclerosis (31). Hence, we hypothcaFGFR1 mice was reduced, it remained slightly elevated comesized that EC FGFR signaling might reduce EndMT to protect
pared with normoxia controls. This suggests that EC FGFR may
J Clin Invest. 2021;131(17):e141467 https://doi.org/10.1172/JCI141467
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Figure 10. Effect of FGFR inhibition on genes
involved in TGF-β–mediated endothelialmesenchymal transition in human pulmonary
artery endothelial cells (HPAECs). Relative
RNA expression of components of the TGF-β
pathway and mesenchymal markers during
EndMT in HPAECs exposed to hypoxia for (A)
48 hours or (B) 14 days compared with controls
in normoxia, with or without FGFR inhibitor
BGJ398, n = 3. Statistical significance was
determined by 2-way ANOVA with Holm-Šídák
multiple comparison test. Closed circles,
HPAECs in normoxia treated with vehicle;
closed squares, HPAECs in normoxia treated
with BGJ398; open circles, HPAECs in hypoxia
treated with vehicle; open squares, HPAECs in
hypoxia treated with BGJ398. (C) Relative RNA
expression of Fgf2 and downstream FGF signaling targets Etv4, Etv5, and Dusp6 in HPAECs
exposed to 14 days of hypoxia compared with
controls in normoxia, n = 3. Statistical significance was determined by 2-tailed, unpaired
Student’s t test. *P < 0.01, **P < 0.05. All data
are shown as the mean ± SEM.

only partially suppress TGF-β signaling, but that this is sufficient
for PH phenotype rescue. SNAI1 and SNAI2 are known to mediate
hypoxia-induced EndMT (70) and combined SNAI1 overexpression and TGF-β2 treatment markedly induced EndMT, resulting
in endothelial and mesenchymal marker changes along with EC
migration (71). In support of our findings that FGFR signaling regulated Snai1 and Snai2 expression, Cooley et al. and Medici et al.
showed the EndMT is regulated by a TGF-β–activated Smad2/3/
SNAI2–dependent signaling pathway (72, 73). Collectively, our
in vivo expression data show that FGFR signaling regulates the
TGF-β/SMAD pathway–dependent expression of downstream
EndMT mediators. We noted that the lack of change in Pecam1
and Acta2 expression in doxycycline-treated hypoxia-exposed
mice and their normoxia littermates may be due to the effect of
12

doxycycline treatment, which increased VE-cadherin expression
to enhance EC adherens junctions (74).
TGF-β signaling has been shown to regulate EndMT in ECs in
vitro (29, 45) and inhibition of FGF signaling together with TGF-β
stimulation can augment Smad2/3 phosphorylation (75). Thus,
we asked whether TGF-β signaling was affected by gain or loss of
EC FGF signaling in HPAECs cultured under hypoxic conditions.
First, we showed that short-term (48 hour) inhibition of FGFR signaling increased Tgfb2 expression in normoxia but had no effect
on downstream signaling components. In the presence of hypoxia,
FGFR inhibition with BGJ398 increased expression of Tgfb2 and
downstream mediators and markers of EndMT. To determine the
effect of FGF inhibition on chronic hypoxia, we exposed HPAECs
to 14 days of hypoxia and showed that prolonged hypoxia increased
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Figure 11. Effect of FGFR
inhibition on endothelialmesenchymal transition in
human pulmonary artery
endothelial cells (HPAECs).
(A) Representative images of
CDH5 (red) and αSMA (green)
immunofluorescence in HPAECs
treated with FGFR inhibitor
BGJ398 under hypoxic conditions compared with controls in
normoxia. Scale bar: 10 μm. (B)
Quantification of the number
of colonies of αSMA-positive
cells per culture well in HPAECs
treated with the FGFR inhibitor
BGJ398 under hypoxic conditions compared with controls
in normoxia, n = 4–10. Closed
circles, HPAECs in normoxia
treated with vehicle; open circle,
HPAECs in hypoxia treated
with vehicle; closed squares,
HPAECs in normoxia treated
with inhibitor; open squares,
HPAECs in hypoxia treated with
inhibitor. (C) Representative
Western blots and quantification of p-Smad2/3 normalized
to total Smad proteins, n = 5. (D)
Representative Western blots
and quantification of αSMA
normalized to β-actin, n = 3. See
complete unedited blots in the
supplemental material. Statistical significance was determined
by 2-way ANOVA with HolmŠídák multiple comparison test.
All data are shown as the mean
± SEM. *P < 0.05, **P < 0.01. (E)
Proposed model showing FGF
inhibition of hypoxia-stimulated
TGF-β signaling in endothelial
-mesenchymal transition.

Smad2/3 phosphorylation and elevated EndMT mediators. Notably, we found that Fgf2 and its downstream targets Etv4, Etv5, and
Dusp6 were also elevated after 14 days of hypoxia, suggesting a
negative feedback mechanism of FGF signaling during EndMT.
DUSP6 is a negative feedback regulator of FGFR signaling (76, 77)
and is also known to regulate EC inflammation via NF-κB–mediated ICAM-1 expression (78). This would suggest that the increased
DUSP6 expression is a pro-EndMT response to hypoxia to negatively regulate FGFR signaling and activate the EC inflammatory
process. Previous studies demonstrated EndMT in vitro after 3–4
days of hypoxia with human coronary artery ECs (79) and less than
24 hours of hypoxia with bovine aortic ECs (24). In our system, we
observed colonies of αSMA-expressing cells among HPAECs, indicating EndMT in vitro after 2 weeks of hypoxia. Although primary

ECs can transdifferentiate in vitro when cultured on plastic or
glass, we did not detect this in our cultures. This may be due to several factors: HPAECs were cultured on gelatin-coated dishes using
EC growth media, and dishes were subcultured at lower density
to optimize for 80%–100% confluence at the end of 2 weeks. We
observed that HPAECs that had undergone EndMT were localized
in colonies spread out across the dish. Further studies would need
to be conducted to determine if each colony was clonally propagated. Collectively, these data show that, with FGF inhibition,
HPAECs cultured in prolonged hypoxia can undergo EndMT.
To evaluate whether EndMT occurs in pulmonary conditions
that may contribute to Group 3 PH, we assessed lung samples
from patients with CPFE with documented elevated mean pulmonary artery pressure (mPAP > 25 mmHg). We noted decreased
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Figure 12. FGF signaling in lungs of
patients with combined pulmonary
fibrosis and emphysema. (A) Representative immunofluorescence images
showing expression of ETV5 (green)
and CDH5 (red) in endothelial cells in
lung tissue from patients with CPFE
compared with normal lung tissue
(control). Arrowheads, ETV5+CDH5+
double-positive endothelial cells;
arrows, CDH5+ singly positive endothelial cells. Scale bars: 25 μm and
20 μm (insets). (B) Representative
immunofluorescence images showing
p-Smad2/3 (green) and CDH5 (red)
expression in endothelial cells in lung
tissue from patients with CPFE compared with normal lung tissue (control). Arrowheads, p-SMAD2/3+CDH5+
double-positive endothelial cells;
arrows, CDH5+ singly positive endothelial cells. Scale bars: 5 μm and
20 μm (insets). (C) Quantification of
ETV5+CDH5+ double-positive endothelial cells in CPFE compared with
control lungs, n = 5. (D) Quantification
of p-SMAD2/3+CDH5+ double-positive
endothelial cells in CPFE compared
with control lungs, n = 5. Statistical significance was determined by 2-tailed,
unpaired Student’s t test. *P < 0.05. All
data are shown as the mean ± SEM.

FGFR signaling and increased TGF-β signaling in lung tissue from
these patients. These data are consistent with our mouse model
and in vitro experiments suggesting that activation of FGFR signaling inhibits TGF-β signaling–induced EndMT. Collectively,
these studies support a model in which FGFR signaling modulates
hypoxia-induced EndMT, at least in part, by regulating TGF-β/
SMAD2/3 signaling (Figure 11E).
Expression of Fgf2 is increased after chronic hypoxia in vivo
in mouse and patient samples and in vitro in HPAECs. In CPFE
patients with physiologic changes consistent with PH, we noted
decreased FGFR signaling. Yet, we also showed that constitutive
FGFR1 signaling leads to reduced PH in mice. Although there
was no PH in hypoxia-exposed caFGFR1 mice, we still observed
increased vascular wall thickening in the larger proximal vessels
(Figure 5C), consistent with moderately increased p-Smad2/3
14

and EndMT. This suggests that TGF-β–mediated EndMT is only
partially regulated by EC-caFGFR1 signaling or that other factors independent of EndMT contribute to vascular wall thickening in response to hypoxia.
Our studies show that loss of FGFR signaling in the endothelium results in more severe Group 3 hypoxia-induced PH,
which is in contrast to studies on Group 1 PH (PAH) that suggest that FGFR signaling is pathologic (33, 34, 36) and that inhibition of FGF2 activity is beneficial (33–35). Pulmonary ECs
from PAH patients (PAH-ECs) exhibited higher FGF2 expression (34), increased FGF2 in the culture media, and increased
survival and proliferation when treated with exogenous FGF2
(33). When treated with PAH-EC–conditioned culture media,
smooth muscle cells from PAH patients demonstrated increased
proliferation (36). Downregulation of Apelin, miR-424, and
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miR-503 in PAH-ECs increased FGF2 and FGFR1 expression
and pulmonary artery EC and VSM cell proliferation (35). Using
the monocrotaline-induced model of PH in rats, Izikki et al.
showed that 2 treatments with the VEGFR2 and FGFR1 inhibitor SU5402 reversed the PH effects (34). Our data showing
that FGFR signaling is protective against hypoxia-induced PH
suggests a divergent role for FGF signaling in a disease context–dependent manner. However, these differences may also
be due to the different animal models and that PAH-ECs may
already be sensitized to PH changes compared with HPAECs
isolated from normal lungs.
Hypoxia augments the Kruppel-like factor 4–dependent
(KLF4-dependent) clonal expansion of VSM progenitors in pulmonary arterioles (80). Increased FGF2 expression in PAH-EC–
conditioned media augments VSM cell proliferation (35). We
showed that, after hypoxia exposure, FGF2 expression is increased
in FLK1-DCKO mice and decreased in caFGFR1 mice. FGF-regulated EndMT in hypoxia-exposed ECs may play a partial role in
contributing to increased VSM in the medial layer. Increased paracrine FGF2 expression may play a direct role in VSM cell proliferation. Further studies will be needed to determine the role of FGF
signaling in chronic hypoxia–induced VSM cell proliferation.
We recognize that assessment of gene expression with RNA
generated from whole lungs of hypoxia-exposed mice is a limitation of this study. We considered fluorescence-assisted cell sorting
to isolate ECs; however, the tissue would be exposed to normoxic
conditions for several hours during tissue digestion and cell sorting, and this process would not assess regional differences in ECs.
Furthermore, EC FGF2 expression is amplified by a HIF1α-dependent pathway (38), and chronic but not short-term hypoxic induction of HIF1α in HUVECs is FGF2 dependent. Further studies are
needed to investigate the role of FGF2-HIF1α interactions during
EndMT under chronic hypoxic conditions. Because FGF2-HIF1α
crosstalk can mediate angiogenesis in tumor models (81), additional studies will be needed to determine whether chronic hypoxia induces a similar FGF-HIF1α signaling interaction.
These findings may have important clinical implications for preclinical and clinical studies aimed at preventing patients at risk from
developing chronic hypoxia-induced PH or treating patients with
hypoxia-induced PH. There is a growing recognition of the clinical
importance of hypoxic lung disease. The observation that endogenous FGFR signaling may limit the progression of hypoxia-induced
PH and that further activation of EC FGFR signaling may prevent
key pathological features of hypoxia-induced PH opens potential
avenues to explore biological therapies for this family of diseases.

Methods

Animal care and use. Mice were group housed in a specific pathogen–
free facility with littermates, in breeding pairs, or in a breeding harem
(2 females to 1 male), with food and water provided ad libitum.
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All human participants consented to donate their lung tissues
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